Vitamin D levels during and after high-dose vitamin D supplementation in women with early-stage breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20561-e20561
Author(s):  
Q. J. Khan ◽  
B. F. Kimler ◽  
P. Sharma ◽  
P. S. Reddy ◽  
S. Baxa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Early Stage ◽  
Linear Regression Analysis ◽  
Musculoskeletal Symptoms ◽  
High Dose ◽  
25Ohd Level ◽  
Vitamin D Levels ◽  
High Dose Vitamin

e20561 Background: Experts define vitamin D deficiency as a 25-hydroxyvitamin D (25OHD) level of < 20 ng/ml; a level < 32 ng/ml is considered insufficient for bone health and > 40 ng/ml may be associated with optimum musculoskeletal function and reduced risk for breast cancer. We conducted a study to determine the effect of high dose vitamin D3 at 50,000 IU/wk (HD vitD) on musculoskeletal symptoms from adjuvant letrozole in breast cancer patients. We present here the effectiveness of HD vitD in achieving optimum 25OHD levels and the rate of decline of 25OHD levels after 12 weeks of HD vitD. Methods: The cohort included post-menopausal women with early stage hormone receptor positive breast cancer initiating letrozole treatment. Women with baseline 25OHD levels < 40 ng/ml received 12 weeks of HD vitD. 25OHD levels were assessed at 6 and 12 weeks during HD vitD supplementation and at 3 and 6 months after completing HD vitD but while taking maintenance dose of 600–1000 IU of vitamin D3 daily. Results: 40 women that received HD vitD completed the follow-up phase of the study and are included in this analysis. At entry on study, median 25OHD level was 23 ng/ml; 38% of the women had vitD deficiency, 75% had insufficiency, and 93% had 25OHD levels < 40 ng/ml. Six weeks of HD vitD increased median 25OHD level to 60 ng/ml and another 6 weeks increased it further to 66 ng/ml. With only 6 weeks of HD vitD supplementation, 98% of the women achieved a 25OHD level of > 40 ng/ml. Median 25OHD levels 3 and 6 months after completion of HD vitD were 49 and 40 ng/ml, respectively. The median rate of decrease in vitD levels per month was 6.8% of the level at completion of supplementation. Using linear regression analysis, projected changes in 25OHD levels were calculated for each subject. Median extrapolated time to drop to a 25OHD level of < 40 ng/ml was 6.0 months, to <32 ng/ml was 7.8 months, and to <20 ng /ml was 10.6 months. Conclusions: Supplementation with vitD3 at 50,000 IU/week for 6 weeks is sufficient to achieve a 25OHD level of >40 ng/ml in 98% of postmenopausal women with breast cancer on an AI. After 12 weeks of HD vitD, there is a steady decline in 25OHD levels at a rate of about 7% per month despite continuing on 600 to 1000 IU of D3 daily. Thus, standard doses of D3 are not adequate to maintain 25OHD levels achieved by HD vitD. No significant financial relationships to disclose.

Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e20560-e20560
Author(s):  
Alice C. Shapiro ◽  
Karen K Swenson ◽  
MaryJo Nissen ◽  
Susan Adlis ◽  
Laura Maybon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Linear Regression Analysis ◽  
Joint Stiffness ◽  
Serum Vitamin ◽  
Vitamin D Insufficiency ◽  
Musculoskeletal Symptoms ◽  
Hand Osteoarthritis ◽  
Serum Vitamin D ◽  
Vitamin D Levels

e20560 Background: Up to 40% of women with estrogen positive (ER+) breast cancer treated with aromatase inhibitors (AIs) experience musculoskeletal symptoms (AIMSS) such as bone pain, joint pain, joint stiffness, and muscle weakness that negatively impact functional ability. Previous reports indicate that vitamin D insufficiency is common in this patient population and that D supplementation might attenuate AIMSS by affecting muscle, bone and/or nerve metabolism. To test the association between AIMSS and serum 25(OH)D levels, we analyzed data collected as part of a pilot prospective study assessing instrument effect sizes to measure AIMSS. Methods: Data were analyzed from 58 women, age 61 ± 10 y with a history of ER+ breast cancer stage I-IIIa. AIMSS symptoms were measured at baseline (pre AI) and 6 mo using the Breast Cancer Prevention Trial Musculoskeletal Subscale (BCPT-MS), the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and the Australian-Canadian Hand Osteoarthritis Index (AUSCAN). Serum 25(OH)D was measured by radioimmunoassay (Diasorin liaison, Stillwater, MN). Linear regression analysis was used to determine the association between changes in AIMSS scores (dependent variables) and changes in serum 25(OH)D from baseline to 6 mo, adjusting for age and season. Results: From baseline to 6 mo there were significant increases on all AIMSS measures (BCPT-MS, WOMAC and AUSCAN p<0.02). These increases in AIMSS measures were not associated with the change in serum 25(OH)D from baseline to 6 mo (Δ =11 ng/ml ± 12; p<0.001). Conclusions: Worsening of symptoms during the initial 6 months of AI therapy was not associated with changes in serum 25(OH)D levels. These results suggest that short-term supplementation with 25(OH)D does not attenuate the symptoms of AIMSS in post-menopausal women with ER+ breast cancer during the first 6 mo of AI therapy. However vitamin D insufficiency was uncommon in this study population (mean 25(OH)D at baseline 31 ng/ml ± 10 and 42± 13 ng/ml at 6 mo). Well controlled clinical trials are needed to further our understanding of these relationships. Clinical trial information: NCT01074320.

scholarly journals Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3451
Author(s):  
Justin C. Brown ◽  
Michael H. Rosenthal ◽  
Chao Ma ◽  
Sui Zhang ◽  
Halla S. Nimeiri ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vitamin D ◽  
Body Composition ◽  
Adipose Tissue ◽  
Metastatic Colorectal Cancer ◽  
Vitamin D3 ◽  
Standard Dose ◽  
High Dose ◽  
Tissue Area ◽  
High Dose Vitamin

Skeletal muscle and adipose tissue express the vitamin D receptor and may be a mechanism through which vitamin D supplementation slows cancer progression and reduces cancer death. In this exploratory analysis of a double-blind, multicenter, randomized phase II clinical trial, 105 patients with advanced or metastatic colorectal cancer who were receiving chemotherapy were randomized to either high-dose vitamin D3 (4000 IU) or standard-dose (400 IU) vitamin D3. Body composition was measured with abdominal computed tomography at enrollment (baseline) and after cycle 8 of chemotherapy (16 weeks). As compared with standard-dose vitamin D3, high-dose vitamin D3 did not significantly change body weight [−0.7 kg; (95% CI: −3.5, 2.0)], body mass index [−0.2 kg/m2; (95% CI: −1.2, 0.7)], muscle area [−1.7 cm2; (95% CI: −9.6, 6.3)], muscle attenuation [−0.4 HU; (95% CI: −4.2, 3.2)], visceral adipose tissue area [−7.5 cm2; (95% CI: −24.5, 9.6)], or subcutaneous adipose tissue area [−8.3 cm2; (95% CI: −35.5, 18.9)] over the first 8 cycles of chemotherapy. Among patients with advanced or metastatic colorectal cancer, the addition of high-dose vitamin D3, vs standard-dose vitamin D3, to standard chemotherapy did not result in any changes in body composition.

Sa1779 Vitamin D Modulates T Cell-Mediated Immunity: Results From a Randomized Controlled Trial of Low-Dose and High-Dose Vitamin D3

2014 ◽  
Vol 146 (5) ◽  
pp. S-294 ◽  
Author(s):  
Gauree G. Konijeti ◽  
Matthew R. Boylan ◽  
Yanna Song ◽  
Pankaj Arora ◽  
Frank E. Harrell ◽  
...  
Keyword(s):  
Vitamin D ◽  
Randomized Controlled Trial ◽  
T Cell ◽  
Vitamin D3 ◽  
Low Dose ◽  
Controlled Trial ◽  
High Dose ◽  
Cell Mediated Immunity ◽  
Randomized Controlled ◽  
High Dose Vitamin

Effects of oral vitamin B12 for the treatment of aromatase inhibitors (AI)-related musculoskeletal symptoms in women with early stage breast cancer.

2018 ◽  
Vol 36 (7_suppl) ◽  
pp. 86-86
Author(s):  
Zeina A. Nahleh ◽  
Aleli Campbell ◽  
Rosalinda Heydarian ◽  
Alok Kumar Dwivedi
Keyword(s):  
Breast Cancer ◽  
Vitamin B12 ◽  
Early Stage ◽  
Short Form ◽  
Well Being ◽  
Musculoskeletal Symptoms ◽  
High Dose ◽  
Walking Ability ◽  
Breast Cancer Patients ◽  
Post Intervention

86 Background: Breast cancer patients receiving Aromatase Inhibitor (AI) therapy experience many side effects including arthralgias, myalgias and stiffness of joints. The objective of this study was to evaluate the effect of vitamin B12 supplements on pain related symptoms. Methods: In this study, patients taking AIs and experiencing pain at baseline were given 2500 mcg of vitamin B12 sublingually daily for 90 days. The validated Brief Pain Inventory-Short Form (BPI-SF) questionnaire using a 10 scale rating was evaluated prior and post- intervention. The BPI-SF asseses pain level and its interference with other daily life events on a scale from one to ten, one meaning pain does not interfere. Item 9 from the BPI assesses 7 important dimensions that are reported here. Results: 36 patients were recruited and scores were evaluated at baseline and at 90 days after taking vitamin B12 for general activity, mood, walking ability, normal work, relations with people, and for enjoyment of life post interventions as shown in the table. Conclusions: This study suggests that by taking a high dose of vitamin B12, significant improvement was observed in several dimensions related to pain scales in patients with AI -related musculoskeletal symptoms. Preliminary data confirms that vitamin B12 not only help improve pain, but it also aids in improving patient’s mood, well-being and relations with others. Larger randomized studies are warranted to confirm these promising findings. Clinical trial information: NCT03069313. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document